Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Mayne Pharma raises gross margin despite revenue decline in FY2026

Mayne Pharma reports FY2026 revenue fell to AUD 383.7m (-6%), while gross margin improved to 64.7% (+411 basis points). Adjusted EBITDA dropped 27% to AUD 34.2m, weighed down by higher sales and marketing costs, currency effects and litigation. The company highlights DistributeRx as a growth platform, reports around 5,000 new prescribing physicians and expects further margin improvement and fewer one-off items in FY2027. » Altro su de.investing.com
Mayne Pharma boosts margins despite stagnant revenue and high legal costs

Mayne Pharma reports largely flat revenue of A$212.1m for H1 FY26 while gross margin widened by 390 basis points to 65.3%. Adjusted EBITDA fell 8% to A$28.6m, weighed down by higher operating costs and exceptional legal costs of A$21.3m; operating cash flow dropped 38% to A$16.9m and cash holdings fell to A$67.3m. The dermatology segment saw a clear margin improvement from mix shift and direct sales, while the women’s health segment faced margin pressure despite volume growth. Management’s FY26 focus is on expanding the dermatology distribution strategy, monetising international investments and controlling legal costs to improve cash flow. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2023, Mayne Pharma Group ha già distribuito 0,0179 € di dividendi. L'ultimo pagamento è avvenuto a gennaio 2023.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Mayne Pharma Group ha registrato ricavi pari a 103,78 Mln € e un utile netto di 23,84 Mln €

(EUR)	giugno 2026	YoY
Ricavi	103,78 Mln	-
Utile lordo	50,55 Mln	-
Utile netto	23,84 Mln	-
EBITDA	1,41 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	161,29 Mln €
Numero di azioni	81,25 Mln
Massimo/minimo a 52 settimane	3,45 € - 1,21 €
Dividendi	No
Beta	1,00
Rapporto P/E	10,13
Rapporto PEG	0,07
Rapporto P/B	0,65
Rapporto P/S	0,66

Profilo aziendale

Die Mayne Pharma Group Limited, ein Spezialpharmaunternehmen, produziert und vertreibt pharmazeutische Markenprodukte und Generika in Australien, den Vereinigten Staaten, Asien und international. Das Unternehmen ist in vier Segmenten tätig: Generische Produkte, Spezialprodukte, Metrics Contract Services und Mayne Pharma International. Das Unternehmen bietet orale Arzneimittelverabreichungssysteme, pharmazeutische Auftragsentwicklung, Herstellung und analytische Dienstleistungen für Drittkunden an und vertreibt pharmazeutische Spezialprodukte in den Therapiebereichen Dermatologie, Frauengesundheit und Infektionskrankheiten. Das Unternehmen war früher unter dem Namen Halcygen Pharmaceuticals Limited bekannt und änderte im November 2010 seinen Namen in Mayne Pharma Group Limited. Die Mayne Pharma Group Limited wurde im Jahr 2005 gegründet und hat ihren Sitz in Salisbury South, Australien.